ArticleAmerican journal of respiratory and critical care medicine2016
Galectin-3 Is Associated with Restrictive Lung Disease and Interstitial Lung Abnormalities.
Article in American journal of respiratory and critical care medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 78 citations in OpenAlex.
- Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1).Cancer chemotherapy and pharmacology · 2024Trial
- Interstitial lung abnormalities: a mechanistic window into early fibrotic lung disease.Frontiers in medicine · 2026Review
- Interstitial Lung Abnormality in Health Screening Examinees: Prevalence, Outcomes, and Risk Factors.Journal of Korean medical science · 2025Article
- Clusters of multidimensional exercise response patterns and estimated heart failure risk in the Framingham Heart Study.ESC heart failure · 2024Article
- Review
- Biomarkers in idiopathic pulmonary fibrosis: Current insight and future direction.Chinese medical journal pulmonary and critical care medicine · 2024Article
- Galectin-3 levels in children with cystic fibrosis.European journal of pediatrics · 2024Article
- Article
- Approach to Clinical Trials for the Prevention of Pulmonary Fibrosis.Annals of the American Thoracic Society · 2023Article
- A genomic perspective of the aging human and mouse lung with a focus on immune response and cellular senescence.Immunity & ageing : I & A · 2023Article
- Increased Levels of Galectin-3 in Critical COVID-19.International journal of molecular sciences · 2023Article
- Decreased Expression of Pulmonary Homeobox NKX2.1 and Surfactant Protein C in Developing Lungs That Over-Express Receptors for Advanced Glycation End-Products (RAGE).Journal of developmental biology · 2023Article
- Circulating galectin-3 levels are inversely associated with subclinical cardiovascular disease in obese adults.Heart and vessels · 2023Article
- Galectin-3 as a Marker for Increased Thrombogenicity in COVID-19.International journal of molecular sciences · 2023Article
- Insights into the Role of Galectin-3 as a Diagnostic and Prognostic Biomarker of Atrial Fibrillation.Disease markers · 2023Review
- Molecular mechanisms of COVID-19-induced pulmonary fibrosis and epithelial-mesenchymal transition.Frontiers in pharmacology · 2023Review
- Markers of Bronchiolitis Obliterans Syndrome after Lung Transplant: Between Old Knowledge and Future Perspective.Biomedicines · 2022Review
- B4GALT1 as a New Biomarker of Idiopathic Pulmonary Fibrosis.International journal of molecular sciences · 2022Article
- [FUT8 modulates galectin-3 expression to regulate TGF-β1-mediated fibrosis of lung fibroblasts].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022Article
- The Proteomic Profile of Interstitial Lung Abnormalities.American journal of respiratory and critical care medicine · 2022Article
Corrections and comments
- Commented on by
Authors and funding
13 authors at 7 institutions in 2 countries.
Funding
Abstract
rationaleGalectin-3 (Gal-3) has been implicated in the development of pulmonary fibrosis in experimental studies, and Gal-3 levels have been found to be elevated in small studies of human pulmonary fibrosis.
objectivesWe sought to study whether circulating Gal-3 concentrations are elevated early in the course of pulmonary fibrosis.
methodsWe examined 2,596 Framingham Heart Study participants (mean age, 57 yr; 54% women; 14% current smokers) who underwent Gal-3 assessment using plasma samples and pulmonary function testing between 1995 and 1998. Of this sample, 1,148 underwent subsequent volumetric chest computed tomography. MEASUREMENTS AND MAIN
resultsHigher Gal-3 concentrations were associated with lower lung volumes (1.4% decrease in percentage of predicted FEV1 per 1 SD increase in log Gal-3; 95% confidence interval [CI], 0.8-2.0%; P < 0.001; 1.2% decrease in percentage of predicted FVC; 95% CI, 0.6-1.8%; P < 0.001) and decreased diffusing capacity of the lung for carbon monoxide (2.1% decrease; 95% CI, 1.3-2.9%; P < 0.001). These associations remained significant after multivariable adjustment (P ≤ 0.008 for all). Compared with the lowest quartile, participants in the highest Gal-3 quartile were more than twice as likely to have interstitial lung abnormalities visualized by computed tomography (multivariable-adjusted odds ratio, 2.67; 95% CI, 1.49-4.76; P < 0.001).
conclusionsElevated Gal-3 concentrations are associated with interstitial lung abnormalities coupled with a restrictive pattern, including decreased lung volumes and altered gas exchange. These findings suggest a potential role for Gal-3 in early stages of pulmonary fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.